Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4263285

Clc1ccc(Nc2nc3nonc3nc2-c2cccc3ccccc23)cc1Cl.N

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.53
MAPT P10636 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
TP53 P04637 3/20 0.44
CCR2 P41597 1/20 0.44
CCR5 P51681 1/20 0.44
NPY5R Q15761 1/20 0.43
POLB P06746 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
TYMS P04818 1/20 0.39
ADORA3 P0DMS8 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4268033 0.88 GUSB (0.45) KDRMAPTSMN1; SMN2TP53CCR2
SCHEMBL3049443 0.82 MAPT (0.49) KDRMAPTSMN1; SMN2TP53CCR2
SCHEMBL3051396 0.78 TP53 (0.55) KDRMAPTSMN1; SMN2TP53CCR2
Ammonia Solution, Strong SCHEMBL4268234 0.76 TP53 (0.52) KDRMAPTSMN1; SMN2TP53CCR2
Ammonia Solution, Strong SCHEMBL4270918 0.75 TUBB4A (0.48) MAPTSMN1; SMN2TP53CCR2CCR5
Ammonia Solution, Strong SCHEMBL4275960 0.74 MAPT (0.46) KDRMAPTSMN1; SMN2TP53CCR2
SCHEMBL3055713 0.74 MAPT (0.50) MAPTSMN1; SMN2TP53CCR2CCR5
Ammonia Solution, Strong SCHEMBL4262270 0.74 MAPT (0.53) KDRMAPTSMN1; SMN2TP53CCR2
SCHEMBL3055646 0.74 TP53 (0.58) KDRMAPTSMN1; SMN2TP53CCR2
Ammonia Solution, Strong SCHEMBL4262241 0.73 GUSB (0.49) KDRMAPTSMN1; SMN2TP53CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US claimed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, RB1, CA5A KDR 3420/4885MAPT 4220/4885SMN1; SMN2 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.